#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.
RSS   Newsletter   Contact   Advertise with us

Ophthotech appoints Glenn Sblendorio as its COO and CFO

Share on Twitter Share on LinkedIn
Staff writer | New York, N.Y., USA | January 7, 2016
OphthotechDecember 7, 2016, New York, N.Y., USA - Ophthotech Corporation, a biopharmaceutical company, announced that Glenn P. Sblendorio it to join the company as EVP, COO and CFO on April 1, 2016.
Mr. Sblendorio is joining Ophthotech from The Medicines Company, where he most recently served as President and Chief Financial Officer. Mr. Sblendorio has more than 30 years of experience in the life sciences sector and is widely known in the investment community and the biotechnology / pharmaceutical industry.

He has held a variety of senior management positions at Hoffmann-LaRoche, Inc., Eyetech Pharmaceuticals Inc. and MPM Capital Advisors, LLC. Mr. Sblendorio has served as a member of the Board of Directors and the Audit Committee Chairman of Ophthotech. Mr. Sblendorio currently serves on the board of directors of Amicus Therapeutics and Intercept Pharmaceuticals.

Mr. Sblendorio holds a Bachelor of Business Administration (B.B.A,) degree from Pace University and a Master of Business Administration (M.B.A.) degree from Fairleigh Dickinson University, and he is a graduate of the Harvard Business School Advanced Management Program.

He will resign as a Director of Ophthotech effective with the assumption of his new executive position, and effective immediately, Mr. Sblendorio will no longer serve on the Audit Committee.

Ophthotech also announced that Michael G. Atieh is retiring as Executive Vice President and Chief Financial and Business Officer of the Company. The Company expects that Mr. Atieh's retirement will be effective as of April 1, 2016.